Publication

Edison issues initiation on Cereno Scientific (CRNO B): Differentiated approach in CVD with potential

Retrieved on: 
Wednesday, March 13, 2024

Cereno Scientific is a clinical-stage biotech, developing treatments for cardiovascular diseases (CVDs) using novel approaches.

Key Points: 
  • Cereno Scientific is a clinical-stage biotech, developing treatments for cardiovascular diseases (CVDs) using novel approaches.
  • Lead asset CS1, a delayed immediate release formulation of valproic acid, is an HDAC inhibitor, aiming to deliver disease-modifying results in pulmonary arterial hypertension (PAH).
  • Preclinical candidates include CS014, for thrombosis prevention without increased risk of bleeding (seen with current antithrombotics), and CS585 for CVD (specific indication not yet determined).
  • As with all Edison publications, Edison controls the editorial and timings of publications and we wish to make it clear that Cereno Scientific had no involvement in the aforementioned issue.

EQS-News: Grand City Properties S.A. announces FY 2023 results with robust operational growth and stable LTV

Retrieved on: 
Wednesday, March 13, 2024

Adjusted EBITDA of €320 million in FY 2023, higher by 4% as compared to €308 million in FY 2022.

Key Points: 
  • Adjusted EBITDA of €320 million in FY 2023, higher by 4% as compared to €308 million in FY 2022.
  • EPRA LTV (considering perpetual notes as debt) as of December 2023 is 48%, up from 46% in December 2022 due to negative property revaluation.
  • Luxembourg, March 13, 2024 – Grand City Properties S.A. (“GCP” or the “Company”) announces results for the financial year 2023 with robust operational performance, strong liquidity position and conservative financial leverage maintained.
  • In 2023, GCP continued its proactive approach of strengthening liquidity, reducing refinance risk and maintaining a conservative financial profile with stable LTV ratio.

EQS-News: STRABAG SE: entry of non-cash capital increase in the commercial register planned for 21 March 2024

Retrieved on: 
Wednesday, March 13, 2024

The entry of the ordinary non-cash capital increase is currently planned for Thursday, 21 March 2024, following expiry of the six-month waiting period in accordance with the Austrian Stock Corporation Act (AktG).

Key Points: 
  • The entry of the ordinary non-cash capital increase is currently planned for Thursday, 21 March 2024, following expiry of the six-month waiting period in accordance with the Austrian Stock Corporation Act (AktG).
  • The new shares from this capital increase are then to be issued immediately to the holders of the existing STRABAG shares with ISIN AT0000A36HH9 (STRABAG SE – Distribution Share-Based Option).
  • The ongoing capital measures were unanimously approved at the 19th Annual General Meeting of STRABAG SE on 16 June 2023.
  • The ordinary non-cash capital increase represents the final step of these capital measures.

Grand City Properties S.A. announces FY 2023 results with robust operational growth and stable LTV

Retrieved on: 
Wednesday, March 13, 2024

Adjusted EBITDA of €320 million in FY 2023, higher by 4% as compared to €308 million in FY 2022.

Key Points: 
  • Adjusted EBITDA of €320 million in FY 2023, higher by 4% as compared to €308 million in FY 2022.
  • EPRA LTV (considering perpetual notes as debt) as of December 2023 is 48%, up from 46% in December 2022 due to negative property revaluation.
  • Luxembourg, March 13, 2024 – Grand City Properties S.A. (“GCP” or the “Company”) announces results for the financial year 2023 with robust operational performance, strong liquidity position and conservative financial leverage maintained.
  • In 2023, GCP continued its proactive approach of strengthening liquidity, reducing refinance risk and maintaining a conservative financial profile with stable LTV ratio.

Unveiling the Future: Nominations Open for Global Blockchain Awards Recognizing Web3 Excellence

Retrieved on: 
Tuesday, March 12, 2024

As a highlight of Dubai's bustling blockchain scene, the Global Blockchain Awards promise to be an unforgettable night celebrating the outstanding contributions of global Web3 leaders.

Key Points: 
  • As a highlight of Dubai's bustling blockchain scene, the Global Blockchain Awards promise to be an unforgettable night celebrating the outstanding contributions of global Web3 leaders.
  • Nominations are now open and can be submitted through the official Global Blockchain Show website: https://www.globalblockchainshow.com/awards/ .
  • Parmar remarks, "Honoring the Web3 changemakers not only recognizes their achievements but also fosters global dissemination of ideas and innovations through the Global Blockchain Awards ceremony."
  • VAP Group is proud to announce that the Global Blockchain Awards are sponsored by VAP Group, a leading consulting firm in the blockchain ecosystem.

IAQG Publishes First IA Standard Through Global Publishing Partner SAE International

Retrieved on: 
Wednesday, February 21, 2024

Brussels, Belgium--(Newsfile Corp. - February 21, 2024) - The International Aerospace Quality Group® (IAQG) announced today the publication of the first International Aerospace (IA) standard, IA9137™: Guidance for the Application of AQAP 2110 within a 9100 Quality Management System.

Key Points: 
  • Brussels, Belgium--(Newsfile Corp. - February 21, 2024) - The International Aerospace Quality Group® (IAQG) announced today the publication of the first International Aerospace (IA) standard, IA9137™: Guidance for the Application of AQAP 2110 within a 9100 Quality Management System.
  • SAE International®, the organization's partner in developing international standards, has released IA9137 globally.
  • As part of this agreement, SAE is publishing IA9137 simultaneously in English, Spanish, German, French, Italian, Japanese, Chinese and Korean.
  • "The publication of IA9137 is a testament to the long-standing relationship between IAQG and SAE – and the worldwide consensus we foster.

Trustifi Launches Geofencing Capabilities in Australia

Retrieved on: 
Monday, March 4, 2024

The Australia Privacy Act is applicable to all private healthcare providers throughout Australia, including practitioners and private hospitals.

Key Points: 
  • The Australia Privacy Act is applicable to all private healthcare providers throughout Australia, including practitioners and private hospitals.
  • Trustifi now offers geofencing in a range of countries, including the US, Canada, Ireland, Germany, Singapore, Brazil, and Australia.
  • Trustifi MSSP partners who work with global end-customers can easily add Australian geofencing capabilities to their client's security plans with one click via a newly implemented software setting.
  • "Trustifi continues to expand its global footprint, offering easy-to-implement compliance capabilities for our customers in a variety of countries.

Fortinet Recognized as a Leader in the 2024 Gartner® Magic Quadrant™ for Enterprise Wired and Wireless LAN Infrastructure

Retrieved on: 
Monday, March 11, 2024

Fortinet believes that this recognition can be attributed to the strength of its Secure Connectivity portfolio—including wired and wireless LAN—which integrates seamlessly with the Fortinet Security Fabric , Fortinet’s unified networking and cybersecurity platform.

Key Points: 
  • Fortinet believes that this recognition can be attributed to the strength of its Secure Connectivity portfolio—including wired and wireless LAN—which integrates seamlessly with the Fortinet Security Fabric , Fortinet’s unified networking and cybersecurity platform.
  • Customers can integrate their wired and wireless LAN into the Fortinet Security Fabric platform through a common operating system, FortiOS .
  • Leveraging network firewall visibility and control enables Fortinet to offer a more robust wired and wireless LAN without the additional cost.
  • Download the report for more information about the 2024 Gartner® Magic Quadrant™ for Enterprise Wired and Wireless LAN Infrastructure.

GreyOrange Recognized in the 2023 Gartner® Market Guide for Retail Store Inventory Management Applications

Retrieved on: 
Friday, March 8, 2024

ATLANTA, March 08, 2024 (GLOBE NEWSWIRE) -- GreyOrange Inc ., a leader in AI-driven fulfillment automation, is honored to be recognized as a Representative Vendor in Gartner® Market Guide for Retail Store Inventory Management Applications, 2023 by analyst Sandeep Unni.

Key Points: 
  • ATLANTA, March 08, 2024 (GLOBE NEWSWIRE) -- GreyOrange Inc ., a leader in AI-driven fulfillment automation, is honored to be recognized as a Representative Vendor in Gartner® Market Guide for Retail Store Inventory Management Applications, 2023 by analyst Sandeep Unni.
  • "We are honored by our recognition in the Gartner Market Guide for Retail Store Inventory Management Applications, in which we see validation for our work in assisting retailers with increased omnichannel inventory management by leveraging real-time data,” said Akash Gupta, Co-Founder and CEO of GreyOrange.
  • Download the Market Guide for Retail Store Inventory Management Applications, compliments of GreyOrange, by visiting https://bit.ly/3V9siLH .
  • Gartner “Market Guide for Retail Store Inventory Management Applications” Sandeep Unni; 6 November 2023.

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

Retrieved on: 
Friday, March 8, 2024

NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming American Academy of Neurology 2024 annual meeting, being held April 13 - 18, 2024, in Dever, Colorado.

Key Points: 
  • NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming American Academy of Neurology 2024 annual meeting, being held April 13 - 18, 2024, in Dever, Colorado.
  • Abstracts are now available online and can be accessed on the AAN meeting website at https://www.aan.com/msa/Public/Events/Index/49 .
  • Details of the upcoming presentations are outlined below.
  • Lead Author: Stephen Krieger, MD - The Corinne Goldsmith Dickinson Center for MS, The Mount Sinai Hospital NY, NY
    Lead Author: Derrick Robertson, MD - University of South Florida (USF) Morsani College of Medicine in Tampa, Florida
    Lead Author: Derrick Robertson, MD - University of South Florida (USF) Morsani College of Medicine in Tampa, Florida
    Following the presentations, the data presented will be available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com/publications.cfm .